Quadrature Capital
FLGT icon

Quadrature Capital’s Fulgent Genetics FLGT Stock Holding History

Quadrature Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,640
Closed -$312K – 1748
2026
Q1 		$312K Buy
+19,640
New +$426K ﹤0.01% 963
2022
Q1 		– Sell
-11,117
Closed -$1.11M – 801
2021
Q4 		$1.11M Buy
11,117
+6,219
+127% +$547K 0.06% 210
2021
Q3 		$441K Sell
4,898
-32,567
-87% -$2.96M 0.02% 410
2021
Q2 		$3.46M Buy
+37,465
New +$2.99M 0.13% 134

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Quadrature Capital's FLGT Position: Q2 2026 in Review

Quadrature Capital sold out of Fulgent Genetics (FLGT) in Q2 2026, closing a stake of 19,640 shares — an estimated $312K sold.

Quadrature Capital first reported a position in FLGT in Q2 2021 and held it in 4 quarters. The position peaked at $3.46M in Q2 2021. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Quadrature Capital reported no remaining Fulgent Genetics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 19,640 Fulgent Genetics shares in Q2 2026, an estimated $312K.
  • Quadrature Capital first reported a position in Fulgent Genetics in Q2 2021 and held it in 4 quarters.
  • Quadrature Capital's Fulgent Genetics position peaked at $3.46M in Q2 2021.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.